Results for untargeted MS search on m/z: (+/-) mode
Details | Name | m/z | RT | RT_Units | Study | Ion_mode | MS_Instrument | Chromatography | Species | Source |
---|---|---|---|---|---|---|---|---|---|---|
AN002019 | 93.03 | 0.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 107.03 | 0.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 109.03 | 0.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 112.99 | 0.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.93 | 11.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 0.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 1.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 1.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 1.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 1.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 2.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 2.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 2.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 3.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 3.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 3.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 3.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 4.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 4.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 5.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 5.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 5.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 6.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 6.32 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 6.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 6.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 7.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 7.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 7.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 8.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 8.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 9.2 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 9.77 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 10.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 10.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 10.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 11.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 11.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 114.94 | 11.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.93 | 8.46 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 0.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 0.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 1.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 1.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 1.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 2.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 2.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 2.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 2.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 3.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 3.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 4.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 4.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 5.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 5.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 5.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 6.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 116.94 | 8.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 123.9 | 11.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 123.91 | 3.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 125.9 | 3.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 125.9 | 11.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 127.9 | 3.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 127.9 | 11.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 134.04 | 0.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 146.91 | 0.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 157.06 | 0.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 157.13 | 2.96 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 157.13 | 3.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 158.05 | 0.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 158.06 | 0.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 165.04 | 5.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 169.07 | 0.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 197.16 | 0.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 199.08 | 0.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 0.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 1.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 1.46 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 1.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 1.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 1.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 2.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 2.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 2.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 2.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 3.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 3.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 3.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 3.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 3.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 4.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 4.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 5.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 5.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 6.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 6.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 7.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 7.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 7.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 9.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 10.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 10.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 10.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 11.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 11.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 203.87 | 11.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 0.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 1.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 1.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 1.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 1.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 2.32 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 2.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 2.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 3.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 3.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 3.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 3.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 4.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 4.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 5.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 5.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 6.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 6.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 6.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 7.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 7.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 7.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 9.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 10.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 10.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 10.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 11.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 11.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 205.87 | 11.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 0.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 1.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 1.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 1.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 2.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 2.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 2.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 2.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 3.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 3.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 3.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 3.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 3.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 4.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 4.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 5.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 5.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 5.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 6.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 6.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 6.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 6.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 7.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 7.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 7.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 9.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 10.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 10.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 10.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 11.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 207.87 | 11.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 1.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 1.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 1.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 1.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 2.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 2.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 3.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 3.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 3.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 4.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 4.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 5.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 5.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 6.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 6.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 7.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 7.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 7.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 8.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 10.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 10.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 10.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 10.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 11.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 11.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 212.84 | 11.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 5.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 5.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 7.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 8.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 10.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 10.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 10.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 11.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 11.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 11.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.83 | 11.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 1.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 1.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 1.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 2.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 2.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 2.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 3.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 3.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 3.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 4.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 4.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 5.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 6.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 7.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 214.84 | 7.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 215.04 | 0.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 1.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 2.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 2.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 3.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 3.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 4.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 4.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 5.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 5.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 5.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 6.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 6.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 7.22 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 7.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 8.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 9.99 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 10.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 10.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 11.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 11.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 11.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.83 | 11.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.84 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.84 | 1.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.84 | 1.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 216.84 | 2.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 221.8 | 5.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 223.03 | 5.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 223.8 | 3.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 223.8 | 5.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 223.8 | 10.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 223.8 | 11.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 223.8 | 11.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (14:1) (physeteric acid) | 225.1908 | 1.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 225.8 | 5.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (14:0) (myristic acid) | 227.2063 | 1.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 239.06 | 5.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 239.06 | 10.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 242.18 | 2.96 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 242.18 | 3.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 244.07 | 0.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 246.19 | 0.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 248.96 | 0.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (16:1) (palmitoleic acid) | 253.2217 | 1.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 254.92 | 0.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 256.91 | 0.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (16:0)-d3 iSTD | 258.2558 | 2.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 266.15 | 0.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 267.24 | 2.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 271.23 | 0.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 276.17 | 1.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 277.19 | 0.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 277.22 | 1.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (18:2) (linoleic acid) | 279.2375 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 281.25 | 1.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 281.25 | 2.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (18:1) (oleic acid) | 281.2532 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 282.26 | 2.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 283.27 | 3.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 0.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 2.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 2.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 3.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 3.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 3.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 3.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 4.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 4.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 4.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 5.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 5.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 6.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 6.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 6.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 6.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 7.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 7.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.8 | 7.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.81 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.81 | 1.2 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.81 | 1.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.81 | 1.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.81 | 1.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 292.81 | 2.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.07 | 0.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 0.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 1.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 1.46 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 1.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 1.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 2.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 2.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 2.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 3.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 3.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 3.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 3.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 4.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 4.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 4.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 5.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 5.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 6.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 6.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 6.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 7.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 7.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 7.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 8.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 10.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 294.8 | 10.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 295.23 | 0.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 295.27 | 3.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 2.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 2.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 2.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 3.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 3.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 3.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 3.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 4.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 4.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 296.8 | 5.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 297.25 | 0.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 298.25 | 1.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 299.17 | 0.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 299.26 | 1.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 299.26 | 1.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (20:5) (eicosapentaenoic acid) | 301.2215 | 1.46 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 301.77 | 2.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 301.77 | 2.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 301.77 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 301.77 | 3.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 301.77 | 3.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 301.77 | 4.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 301.77 | 4.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 301.77 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (20:4) (arachidonic acid) | 303.2375 | 1.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 303.77 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 1.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 2.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 2.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 2.77 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 3.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 4.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 4.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 6.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 6.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 10.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 10.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 303.77 | 11.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.02 | 0.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (20:3) (eicosatrienoic acid) | 305.2515 | 2.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | FA (20:3) (homo-gamma-linolenic acid) | 305.253 | 2.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 305.76 | 2.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.76 | 3.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.77 | 2.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.77 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.77 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.77 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.77 | 4.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 305.77 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 307.16 | 0.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (20:2) (eicosadienoic acid) | 307.268 | 2.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 308.27 | 2.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 309.18 | 0.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 309.21 | 1.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (20:1) (eicosenoic acid) | 309.2835 | 3.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 310.74 | 5.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 311.3 | 3.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 312.73 | 2.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 312.73 | 2.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 312.73 | 3.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 312.73 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 312.73 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 313.08 | 5.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 314.73 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 314.73 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 314.73 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 315.14 | 0.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 322.21 | 0.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 322.21 | 0.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 325.17 | 0.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 326.27 | 1.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (22:6) (docosahexaenoic acid) | 327.2374 | 1.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 329.09 | 0.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 329.18 | 0.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 329.25 | 2.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 330.26 | 2.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 332.27 | 2.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 333.28 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 335.22 | 1.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (22:2) (docosadienoic acid) | 335.2983 | 3.46 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 337.21 | 1.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (22:1) (erucic acid) | 337.3137 | 3.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 337.91 | 10.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 337.91 | 11.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 337.91 | 11.32 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 337.91 | 11.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 339.2 | 0.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | CUDA iSTD | 339.2699 | 0.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 339.9 | 11.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 339.9 | 11.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 339.9 | 11.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 339.91 | 10.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 339.91 | 10.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 346.87 | 11.83 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 348.87 | 11.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 353.2 | 0.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 353.35 | 4.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 358.3 | 2.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 359.19 | 0.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 359.23 | 1.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 361.24 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 362.29 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 363.25 | 2.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 363.26 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 363.33 | 4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 364.26 | 2.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 364.33 | 3.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 365.27 | 2.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 365.27 | 3.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 365.35 | 4.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 367.25 | 4.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 367.36 | 5.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 368.08 | 0.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 368.36 | 5.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 369.24 | 4.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 377.28 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 381.24 | 1.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 381.38 | 5.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 385.24 | 1.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 389.29 | 2.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 391.27 | 0.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 391.36 | 4.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 392.7 | 3.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 393.38 | 5.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 393.38 | 5.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 394.7 | 3.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 395.25 | 0.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 395.25 | 1.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 395.39 | 5.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | FA (26:0) (cerotic acid) | 395.3915 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 397.34 | 3.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 397.37 | 3.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 398.29 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 400.3 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | MAG (17:0/0:0/0:0) iSTD | 403.3105 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 409.24 | 1.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 409.25 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 409.37 | 3.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 411.39 | 3.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 411.39 | 3.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 415.31 | 2.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 421.23 | 0.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 426.84 | 2.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 426.84 | 2.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 426.84 | 3.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 426.84 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 426.84 | 3.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 428.34 | 2.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 428.84 | 3.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 428.84 | 3.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 436.2867 | 1.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 437.23 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 437.8 | 3.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 439.24 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 441.4 | 3.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 443.24 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 445.26 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 445.34 | 1.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 445.34 | 2.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 446.26 | 2.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPE (16:0) | 452.2818 | 1.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 455.42 | 4.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 462.3 | 1.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPE (17:1) iSTD | 464.2829 | 1.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 464.32 | 2.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 465.31 | 2.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 466.3 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 473.29 | 1.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 473.31 | 3.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPE (18:2) | 476.2824 | 1.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 478.29 | 1.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 478.2971 | 1.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 478.3 | 1.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 479.32 | 3.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 480.31 | 2.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPE 18:0; | 480.313 | 2.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 480.3134 | 1.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 483.46 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 489.26 | 1.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 489.28 | 1.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 493.34 | 3.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 495.32 | 3.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 498.93 | 0.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPE (20:4) | 500.2816 | 1.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 504.3141 | 1.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 506.29 | 1.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 506.3286 | 1.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 508.34 | 2.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 508.34 | 2.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 509.29 | 1.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 509.33 | 3.22 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 511.48 | 2.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPE (22:6) | 524.2817 | 1.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 525.25 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (14:0) | 526.3182 | 1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 527.26 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 527.45 | 7.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 528.28 | 1.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 528.31 | 1.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 530.3 | 1.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d34:2) | 534.4895 | 5.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 536.51 | 5.83 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 538.35 | 1.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 540.37 | 1.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d32:1) | 544.4507 | 5.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 547.31 | 2.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (16:1) | 552.3339 | 1.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 554.35 | 1.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (16:0) | 554.3508 | 1.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 557.46 | 3.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 558.46 | 3.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d33:1) | 558.4669 | 5.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 559.48 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 562.31 | 2.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 563.51 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 564.54 | 6.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 567.51 | 5.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (17:0) iSTD | 568.3665 | 1.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 568.4 | 2.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d34:1) | 572.483 | 5.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 574.48 | 5.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (18:2) | 578.3515 | 1.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 580.36 | 1.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 580.36 | 1.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (18:1) | 580.3658 | 1.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | LPC (18:0) A | 582.3812 | 2.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | LPC (18:0) B | 582.3817 | 2.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 583.38 | 3.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 585.49 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d18:1/17:0) iSTD | 586.5004 | 6.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 591.39 | 2.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 593.12 | 4.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 593.48 | 3.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 593.48 | 3.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 595.5 | 3.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d34:0) | 598.5411 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 599.32 | 1.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 599.5 | 5.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 599.54 | 6.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d36:1) | 600.5143 | 6.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | LPC 20:4; | 602.3501 | 1.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 602.51 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 603.35 | 1.15 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (20:3) | 604.3656 | 1.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | LPC (20:2) | 606.3806 | 1.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | LPC (20:1) | 608.3949 | 2.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 609.44 | 2.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 610.41 | 3.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 610.55 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 611.51 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 613.53 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 616.47 | 4.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 618.58 | 7.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 620.6 | 7.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 622.54 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 622.54 | 6.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 625.56 | 6.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 626.34 | 1.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 627.53 | 6.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | LPC (22:5) | 628.3651 | 1.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 628.55 | 7.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 629.49 | 7.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 630.55 | 7.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 634.62 | 8.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 636.35 | 1.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 639.43 | 5.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 642.56 | 7.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 644.6 | 7.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 646.62 | 8.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 647.62 | 7.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 647.62 | 8.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 648.63 | 8.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 650.57 | 6.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d38:1) | 652.59 | 7.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 653.49 | 6.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 654.56 | 7.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 655.42 | 2.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 655.51 | 7.2 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 655.55 | 7.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 656.56 | 7.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 656.58 | 7.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 657.56 | 7.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 658.59 | 8.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 659.18 | 0.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 659.5151 | 4.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 659.52 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 660.35 | 1.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 660.59 | 8.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 662.37 | 1.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 663.46 | 2.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 664.38 | 2.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 664.38 | 2.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 667.49 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 668.58 | 7.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 668.58 | 7.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 669.58 | 7.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 670.48 | 4.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 670.59 | 8.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 32:2e; PE 16:1e/16:1; | 672.499 | 5.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 672.61 | 8.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 673.48 | 5.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 673.51 | 5.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 673.5309 | 4.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 674.51 | 6.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 674.59 | 7.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 675.52 | 6.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 678.61 | 7.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 679.61 | 7.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 680.5773 | 7.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d40:1) | 680.6219 | 7.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 681.57 | 7.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 681.58 | 7.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d42:2) A | 682.5933 | 7.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | Ceramide (d42:2) B | 682.5938 | 7.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 683.6 | 7.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 683.64 | 8.2 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 684.6 | 8.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d42:1) | 684.6093 | 8.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 685.5305 | 4.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 685.6 | 7.99 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 685.61 | 8.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 686.51 | 5.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 686.59 | 7.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 686.61 | 8.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d42:0) | 686.6234 | 8.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 687.55 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 687.61 | 8.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 687.63 | 8.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 688.49 | 5.2 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 688.62 | 8.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 690.51 | 5.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 691.45 | 2.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 692.62 | 7.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 692.62 | 7.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 692.62 | 7.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 693.62 | 7.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 693.62 | 7.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (12:0/13:0) iSTD | 694.4681 | 3.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 694.64 | 8.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 694.64 | 8.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 695.6 | 7.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 696.61 | 8.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 696.65 | 8.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 696.65 | 8.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 697.6115 | 8.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 698.47 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (p-34:2) or PE (o-34:3) | 698.5148 | 5.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 698.56 | 5.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 698.61 | 8.15 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 698.62 | 8.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 699.48 | 8.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 699.51 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 699.63 | 8.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 700.49 | 5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 700.53 | 5.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 700.53 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (p-34:1) or PE (o-34:2) | 700.5302 | 6.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 700.57 | 7.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 700.6 | 7.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 700.6 | 8.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 700.62 | 8.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 701.53 | 6.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 702.51 | 5.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 34:1e; PE 18:1e/16:0; | 702.5449 | 6.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 702.55 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 702.62 | 8.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 703.55 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 704.62 | 7.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 704.63 | 7.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 705.55 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 706.64 | 8.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 707.6 | 7.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 707.64 | 8.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 708.64 | 7.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 708.65 | 8.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 709.61 | 8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 709.6119 | 7.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 711.62 | 7.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 711.6282 | 8.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 711.67 | 8.83 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 712.49 | 4.99 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 712.49 | 9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 712.53 | 5.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 712.53 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 712.63 | 8.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | Ceramide (d44:1) | 712.6389 | 9.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 713.5 | 9.32 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 713.5615 | 5.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 713.63 | 8.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 713.64 | 8.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 713.64 | 9.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (34:2) | 714.5096 | 5.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 714.54 | 6.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 35:2e; | 714.5449 | 6.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | GlcCer(d14:1(4E)/20:0(2OH)) | 714.5551 | 5.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 715.5771 | 5.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 716.52 | 5.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (34:1) | 716.5251 | 5.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 717.53 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 718.35 | 1.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 718.54 | 5.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (17:0/17:0) iSTD | 718.5421 | 6.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 718.65 | 8.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 32:1; PG 14:0-18:1; | 719.4869 | 3.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 36:6e; PE 16:1e/20:5; | 720.4992 | 5.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 720.65 | 8.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 721.5 | 4.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 32:0; | 721.5026 | 4.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (p-36:4) or PE (o-36:5) | 722.5155 | 5.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 723.67 | 8.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 724.53 | 5.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 724.53 | 5.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 36:4e; PE 16:1e/20:3; | 724.5303 | 5.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 725.53 | 5.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 725.64 | 8.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 726.5 | 9.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 726.54 | 5.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 726.54 | 5.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 36:3e; PE 18:2e/18:1; | 726.5463 | 6.22 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (p-36:2) or PE (o-36:3) | 726.5464 | 6.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 726.58 | 7.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 726.58 | 7.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 727.51 | 9.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 728.52 | 5.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 728.56 | 6.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 728.56 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (p-36:1) or PE (o-36:2) | 728.5615 | 6.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 728.6 | 7.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 728.63 | 7.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 729.53 | 5.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 729.56 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 729.56 | 6.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 730.54 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 730.54 | 6.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 730.57 | 7.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 730.58 | 6.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 730.65 | 7.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 730.65 | 8.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 731.54 | 6.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 731.58 | 6.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 731.65 | 7.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 732.5 | 5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 732.52 | 4.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 732.65 | 7.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 732.66 | 8.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 734.5352 | 5.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 734.67 | 8.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d34:2) | 735.5227 | 4.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 36:5; PE 16:0-20:5; | 736.4925 | 4.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 736.52 | 4.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 736.5298 | 5.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 736.53 | 5.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 737.52 | 4.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 737.53 | 5.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (36:4) | 738.5095 | 5.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 738.51 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 738.53 | 4.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 738.54 | 4.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 739.53 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 740.52 | 5.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (36:3) | 740.5251 | 5.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 741.53 | 5.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 742.54 | 5.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (36:2) | 742.5413 | 6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 743.54 | 5.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 743.61 | 6.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 744.55 | 5.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (36:1) | 744.5564 | 5.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 745.5 | 4.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 34:2; PG 16:1-18:1; | 745.5028 | 3.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 745.55 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 745.56 | 6.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 746.51 | 4.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 38:7e; PE 18:2e/20:5; | 746.514 | 5.15 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (p-38:6) or PE (o-38:7) | 746.5148 | 5.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 746.56 | 6.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 747.52 | 4.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 747.52 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 747.52 | 5.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 34:1; PG 16:0-18:1; | 747.5203 | 4.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 748.52 | 4.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 748.53 | 5.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (p-38:5) or PE (o-38:6) | 748.5309 | 5.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 749.49 | 2.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 749.53 | 5.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG (17:0/17:0) iSTD | 749.5374 | 5.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 750.51 | 4.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 38:5e; PE 16:0e/22:5; | 750.5442 | 5.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 38:5e; PE 16:1e/22:4; | 750.5458 | 6.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (p-38:4) or PE (o-38:5) | 750.5469 | 6.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 750.56 | 5.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 751.55 | 5.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 751.55 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 751.55 | 6.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 752.53 | 5.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 752.56 | 5.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 752.56 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 38:4e; PE 18:0e/20:4; | 752.5608 | 6.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (p-38:3) or PE (o-38:4) | 752.5613 | 6.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 753.56 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 754.56 | 6.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (p-38:2) or PE (o-38:3) | 754.5771 | 6.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 754.58 | 7.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 755.58 | 7.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 756.56 | 6.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 756.56 | 6.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 756.59 | 7.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 38:2e; PE 16:1e/22:1; | 756.5925 | 7.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 758.58 | 5.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 758.6 | 7.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PS 34:1; PS 16:0-18:1; | 760.5145 | 4.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 760.53 | 5.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 761.54 | 4.96 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 761.55 | 5.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d34:1) | 761.5844 | 4.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (38:6) | 762.5097 | 5.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 762.51 | 4.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 762.53 | 4.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 762.54 | 5.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 762.55 | 5.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 763.51 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 763.55 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d34:0) | 763.5969 | 5.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 38:5; PE 18:0-20:5; | 764.525 | 5.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 38:5; PE 18:1-20:4; | 764.5253 | 5.32 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 764.55 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 764.59 | 4.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 765.53 | 5.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 766.54 | 4.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 766.54 | 5.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 766.54 | 5.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (38:4) A | 766.5405 | 5.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (38:4) B | 766.5419 | 5.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 767.54 | 4.83 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 767.54 | 5.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 768.5488 | 5.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 38:3; PE 18:1-20:2; | 768.5558 | 6.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 38:3; PE 18:0-20:3; | 768.5558 | 6.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 769.56 | 5.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 769.56 | 6.2 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 769.62 | 6.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 769.62 | 7.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 770.56 | 6.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 770.57 | 5.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (38:2) | 770.5714 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 38:2; PE 18:1-20:1; | 770.5717 | 6.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 38:2; PE 18:0-20:2; | 770.5718 | 6.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PG 36:3; PG 18:1-18:2; | 771.518 | 4.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 771.57 | 5.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 771.64 | 7.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (p-40:7) or PE (o-40:8) | 772.53 | 5.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 772.5871 | 6.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 772.59 | 7.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 772.64 | 6.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 773.53 | 4.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 773.53 | 4.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 773.53 | 5.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 36:2; PG 18:1-18:1; | 773.5355 | 4.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 40:7e; PE 18:2e/22:5; | 774.5458 | 5.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (p-40:6) or PE (o-40:7) | 774.546 | 6.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 774.55 | 5.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 774.56 | 5.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 775.55 | 4.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 775.55 | 4.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 775.55 | 5.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 36:1; PG 18:0-18:1; | 775.5521 | 5.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | SM (d18:1/17:0) iSTD | 775.5986 | 5.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 776.56 | 5.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 776.56 | 5.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 776.56 | 6.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (p-40:5) or PE (o-40:6) | 776.5615 | 6.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 776.58 | 6.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC 32:1e; PC 16:0e/16:1; | 776.5814 | 5.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 777.47 | 5.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 777.55 | 5.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 777.56 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 777.58 | 4.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 777.58 | 6.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 777.59 | 6.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 778.52 | 3.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 778.56 | 5.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:5e; PE 18:1e/22:4; | 778.5779 | 6.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE (p-40:4) or PE (o-40:5) | 778.5783 | 6.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 778.58 | 5.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 778.58 | 6.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC 32:0e; PC 16:0e/16:0; | 778.597 | 6.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 779.58 | 6.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 779.59 | 6.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 780.56 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 780.58 | 7.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 780.59 | 6.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:4e; PE 18:2e/22:2; | 780.5914 | 6.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 781.5 | 5.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 782.53 | 6.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 782.56 | 3.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:3e; PE 18:1e/22:2; | 782.6076 | 7.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 782.65 | 7.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 783.66 | 7.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:2e; PE 18:1e/22:1; | 784.6233 | 8.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | SM (d36:3) | 785.5826 | 4.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 785.66 | 7.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PS 36:2; PS 18:1-18:1; | 786.5294 | 4.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 786.53 | 4.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d36:2) | 787.5983 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 788.53 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PS 36:1; PS 18:0-18:1; | 788.5457 | 5.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (32:2) | 788.5461 | 4.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 788.55 | 5.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 788.55 | 5.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 788.6 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 789.53 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d36:1) | 789.6144 | 5.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 790.54 | 5.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 790.54 | 5.46 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE (40:6) | 790.5405 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 40:6; PE 18:0-22:6; | 790.5408 | 5.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (32:1) | 790.562 | 5.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 790.6 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 791.54 | 5.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 792.53 | 5.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 792.55 | 5.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:5; PE 18:0-22:5; | 792.5563 | 5.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 792.56 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 792.56 | 5.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 792.56 | 6.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (32:0) | 792.5779 | 5.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PG 38:6; PG 16:0-22:6; | 793.5026 | 3.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 793.55 | 5.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 793.6 | 6.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 794.51 | 3.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 794.54 | 5.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (34:1) | 794.5513 | 5.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 794.57 | 5.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 794.57 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:4; PE 18:0-22:4; | 794.5716 | 6.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 795.52 | 3.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 795.56 | 5.77 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 795.58 | 5.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 795.64 | 6.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 796.55 | 5.77 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:3; PE 18:1-22:2; | 796.5868 | 6.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 796.59 | 6.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 38:4; PG 18:1-20:3; | 797.5331 | 4.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 797.65 | 7.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 797.66 | 7.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 798.53 | 5.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 40:2; PE 18:0-22:2; | 798.6026 | 7.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 798.66 | 7.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 38:3; PG 18:1-20:2; | 799.5498 | 4.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 799.67 | 7.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-34:2) or PC (o-34:3) | 800.5823 | 5.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PE 40:1; PE 22:0-18:1; | 800.6181 | 7.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PG 38:2; PG 18:1-20:1; | 801.5665 | 4.96 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 801.58 | 5.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 802.56 | 5.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (33:2) | 802.5615 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 802.58 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-34:1) or PC (o-34:2) A | 802.5975 | 5.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (p-34:1) or PC (o-34:2) B | 802.5979 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 803.57 | 4.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 803.57 | 5.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 803.62 | 6.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 804.52 | 5.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (33:1) | 804.5771 | 5.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 804.6 | 6.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-34:0) or PC (o-34:1) | 804.6139 | 6.17 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 805.52 | 5.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 805.62 | 6.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 806.6 | 7.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 806.6 | 7.96 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC 34:0e; PC 18:0e/16:0; | 806.6287 | 6.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 32:1; PI 16:0-16:1; | 807.5039 | 4.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 808.55 | 6.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 808.55 | 6.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 808.61 | 8.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 808.67 | 7.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 32:0; PI 16:0-16:0; | 809.5193 | 4.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 809.55 | 6.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 809.62 | 8.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PS 38:4; PS 18:0-20:4; | 810.5298 | 4.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 810.53 | 4.96 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 810.53 | 5.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 810.56 | 6.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PE 42:3e; | 810.6384 | 8.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 810.68 | 7.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (34:4) | 812.5458 | 4.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 814.56 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (34:3) | 814.5618 | 4.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 815.55 | 4.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 815.57 | 4.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d38:2) | 815.6294 | 5.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (36:4) B | 816.534 | 5.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 816.56 | 4.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 816.56 | 5.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (34:2) | 816.5785 | 5.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 816.58 | 5.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 816.61 | 6.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM d38:1; SM d14:1/24:0; | 817.6453 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (36:3) A | 818.5494 | 5.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 818.59 | 6.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | GlcCer (d40:1) | 818.6293 | 7.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PG 40:7; PG 18:1-22:6; | 819.5189 | 3.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 819.6 | 5.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 819.64 | 7.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 819.64 | 7.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 819.65 | 6.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 820.53 | 4.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (36:2) | 820.5641 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 820.6 | 5.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (34:0) | 820.6113 | 6.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 821.57 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM d40:1; SM d14:1/26:0; | 821.6334 | 7.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 822.56 | 5.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (36:1) | 822.5809 | 6.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 822.63 | 7.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 822.64 | 10.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 823.58 | 6.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 823.63 | 7.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 824.54 | 6.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 824.58 | 6.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-36:4) or PC (o-36:5) | 824.5822 | 5.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 825.55 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 826.56 | 6.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (35:4) | 826.5612 | 4.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (p-36:3) or PC (o-36:4) | 826.5983 | 5.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 826.6 | 5.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 826.63 | 7.79 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 827.56 | 6.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 827.56 | 6.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PG 40:3; PG 18:1-22:2; | 827.5815 | 4.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 827.6 | 5.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 828.52 | 5.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 828.58 | 5.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 828.61 | 5.83 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 828.61 | 6.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 828.61 | 6.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-36:2) or PC (o-36:3) | 828.6119 | 5.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 828.65 | 8.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 830.53 | 5.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 830.59 | 5.46 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (35:2) | 830.5923 | 5.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (p-36:1) or PC (o-36:2) | 830.629 | 6.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 830.63 | 6.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 830.63 | 6.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 831.59 | 5.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 831.63 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 831.63 | 6.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 831.66 | 6.71 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 832.55 | 6.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 832.6 | 5.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (35:1) | 832.6081 | 6.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | GlcCer (d41:1) | 832.644 | 7.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC 36:1e; PC 18:0e/18:1; | 832.6456 | 6.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 832.65 | 6.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 34:2; PI 16:1-18:1; | 833.5203 | 4.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 833.55 | 6.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 833.61 | 6.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 833.64 | 6.83 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 833.66 | 6.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 834.52 | 4.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 834.53 | 4.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 834.59 | 4.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 834.65 | 7.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 835.53 | 4.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 34:1; PI 16:0-18:1; | 835.5359 | 4.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 835.65 | 7.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 836.54 | 4.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 836.5439 | 4.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 836.58 | 6.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 34:0; PI 16:0-18:0; | 837.5519 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (36:5) A | 838.5612 | 4.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (36:5) B | 838.562 | 4.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 838.59 | 7.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 839.56 | 5.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 839.57 | 4.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (38:6) | 840.5335 | 4.99 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (36:4) A | 840.5781 | 4.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 841.57 | 4.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 841.58 | 4.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 841.58 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d40:3) | 841.6439 | 5.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (36:3) B | 842.5939 | 5.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 842.6 | 5.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 842.63 | 6.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 843.59 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 843.6 | 5.32 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 843.6 | 5.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM d40:2; SM d14:2/26:0; | 843.6611 | 6.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 844.6 | 5.37 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 844.61 | 5.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 844.63 | 6.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 844.64 | 7.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | GlcCer (d42:2) | 844.6464 | 7.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 844.66 | 6.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 845.67 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 845.67 | 6.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 846.58 | 6.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 846.62 | 6.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 846.65 | 7.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | GlcCer (d42:1) | 846.6606 | 7.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 847.54 | 4.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 847.62 | 5.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 847.63 | 6.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 847.65 | 6.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 847.65 | 7.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 847.68 | 6.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 847.69 | 7.31 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 848.54 | 5.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 848.5801 | 6.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 848.65 | 7.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 848.69 | 7.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 849.55 | 4.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 849.55 | 4.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 849.55 | 4.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 849.65 | 7.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 849.66 | 7.94 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM d42:1; SM d14:1/28:0; | 849.6627 | 7.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 850.561 | 4.7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-38:5) or PC (o-38:6) | 850.5961 | 5.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 850.6 | 5.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 850.6 | 5.66 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 850.66 | 7.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 851.6 | 5.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-38:4) or PC (o-38:5) B | 852.613 | 6.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (p-38:4) or PC (o-38:5) A | 852.6134 | 5.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 854.59 | 7.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (37:4) | 854.5922 | 5.49 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC 38:4e; PC 18:0e/20:4; | 854.6289 | 6.21 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 854.63 | 6.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 854.63 | 6.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 855.59 | 5.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 855.64 | 6.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 856.55 | 6.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 856.69 | 7.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 857.52 | 3.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 36:4; PI 16:0-20:4; | 857.5203 | 4.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | SM d41:2; SM d14:2/27:0; | 857.677 | 6.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 857.68 | 6.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 858.56 | 6.22 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 858.62 | 6.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 858.62 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC 38:2e; PC 16:0e/22:2; | 858.6653 | 7.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 858.68 | 6.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 859.53 | 4.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 36:3; PI 18:1-18:2; | 859.5352 | 4.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 859.68 | 6.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM d41:1; SM d14:1/27:0; | 859.6925 | 7.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 860.54 | 4.33 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 860.58 | 6.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 860.59 | 4.99 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 860.61 | 5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 860.64 | 6.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 860.67 | 7.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 36:2; PI 18:1-18:1; | 861.5518 | 4.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 36:2; PI 18:0-18:2; | 861.552 | 4.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 862.56 | 4.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 862.56 | 4.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 863.56 | 4.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 36:1; (PI 18:0-18:1) A; | 863.567 | 5.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 36:1; (PI 18:0-18:1) B; | 863.5672 | 5.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 864.58 | 4.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 865.58 | 4.77 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 36:0; PI 18:0-18:0; | 865.5814 | 5.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 866.58 | 4.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 866.58 | 4.96 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (38:5) B | 866.5924 | 5.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (38:5) A | 866.593 | 5.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 866.67 | 6.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 867.59 | 5.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 867.59 | 5.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 867.66 | 5.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (38:4) A | 868.6097 | 5.81 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 868.61 | 5.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 868.61 | 5.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 868.69 | 7.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 869.6 | 5.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 869.61 | 5.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d42:3) | 869.6771 | 6.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 869.69 | 7.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 870.62 | 5.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 870.62 | 6.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 870.62 | 6.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (38:3) | 870.6251 | 6.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 870.68 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 871.53 | 4.38 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 871.62 | 5.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 871.63 | 5.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 871.63 | 6.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 871.69 | 7.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d42:2) B | 871.6935 | 7.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 872.56 | 5.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (38:2) | 872.64 | 6.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 872.64 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 872.69 | 7.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 872.7 | 7.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 872.72 | 8.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 873.64 | 6.58 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 873.7 | 7.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 873.71 | 7.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 874.58 | 5.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 874.65 | 6.61 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 874.66 | 7.09 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 874.69 | 7.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 874.71 | 7.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 37:2; PI 18:0-19:2; | 875.5668 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 875.66 | 7.11 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 875.72 | 7.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 876.71 | 7.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 880.64 | 6.22 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-40:4) or PC (o-40:5) | 880.6422 | 6.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 881.52 | 3.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 881.52 | 4.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 882.66 | 6.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (p-40:3) or PC (o-40:4) | 882.6608 | 6.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 38:5; PI (18:1-20:4) B; | 883.5353 | 4.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 38:5; PI (18:1-20:4) A; | 883.5356 | 4.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 884.54 | 4.23 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 884.6 | 6.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 884.68 | 7.07 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 38:4; PI 18:1-20:3; | 885.5492 | 4.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 38:4; PI 18:0-20:4; | 885.5525 | 4.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | SM d43:2; SM d14:2/29:0; | 885.7062 | 7.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 886.61 | 5.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 886.62 | 6.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 38:3; PI 18:1-20:2; | 887.5673 | 4.87 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 38:3; PI 18:0-20:3; | 887.5674 | 5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | SM d43:1; SM d14:1/29:0; | 887.7227 | 8.03 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 888.57 | 4.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 888.57 | 5.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 888.62 | 5.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 889.58 | 4.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 889.58 | 5.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 38:2; PI 18:0-20:2; | 889.583 | 5.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (40:7) | 890.5917 | 5.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 891.59 | 5.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 38:1; PI 18:0-20:1; | 891.598 | 5.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 892.57 | 6.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (40:6) B | 892.6085 | 5.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 892.61 | 5.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 892.62 | 5.82 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 892.7 | 7.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 893.6 | 5.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 893.6 | 5.64 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 894.62 | 5.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PC (40:5) A | 894.6233 | 5.83 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PC (40:5) B | 894.6237 | 6.08 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 895.62 | 5.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 896.59 | 5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 896.64 | 6.29 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 896.64 | 6.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 897.55 | 4.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 897.59 | 4.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 898.58 | 5.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 898.65 | 6.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 899.58 | 5.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 899.65 | 6.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | SM (d44:2) | 899.7222 | 7.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 900.59 | 5.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 900.6 | 5.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 900.67 | 7.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 901.58 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 901.58 | 5.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 901.59 | 5.89 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 902.58 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 902.61 | 6.34 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 902.69 | 7.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 903.6 | 5.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 904.7 | 8.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 907.53 | 4.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 908.56 | 6.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 908.6 | 5.53 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 908.68 | 6.9 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 909.55 | 4.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 40:6; PI 18:0-22:6; | 909.5506 | 4.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | PI 40:5; PI 18:0-22:5; | 911.5665 | 4.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 911.57 | 4.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 912.57 | 4.48 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 912.6 | 5.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 913.57 | 4.5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 913.58 | 3.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 40:4; PI 18:0-22:4; | 913.5822 | 5.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 913.66 | 6.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 914.58 | 5.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 914.65 | 6.78 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 915.52 | 4.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 40:3; PI 18:1-22:2; | 915.5978 | 5.27 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 915.6 | 3.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 915.6 | 5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 915.6 | 5.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 916.6 | 4.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 917.54 | 4.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 40:2; PI 18:0-22:2; | 917.614 | 5.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 918.62 | 5.6 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 919.57 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 40:1; PI 18:0-22:1; | 919.6284 | 6.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 920.63 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 921.63 | 4.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 922.58 | 4.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 922.58 | 5.14 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 923.57 | 4.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 924.59 | 5.26 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 924.6 | 5.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 924.6 | 5.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 924.68 | 7.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 925.59 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 925.6 | 5.36 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 925.6 | 5.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 925.66 | 6.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 926.58 | 5.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 926.61 | 5.8 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 926.61 | 5.95 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 926.67 | 6.35 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 926.69 | 7.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 927.68 | 7.05 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 928.62 | 6.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 928.63 | 6.44 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 928.7 | 7.67 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 929.68 | 7.02 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 930.72 | 8.3 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 931.67 | 7.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 931.72 | 8.47 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 932.73 | 8.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 933.73 | 9.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 934.69 | 6.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 936.71 | 7.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 937.71 | 7.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 939.52 | 4.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 939.68 | 6.76 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 941.69 | 7.39 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 943.55 | 4.59 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 943.55 | 4.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 944.55 | 4.56 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | PI 42:2; PI 18:0-24:2; | 945.6436 | 6.28 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |
AN002019 | 946.58 | 4.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 946.58 | 4.98 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 946.88 | 11.41 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 948.59 | 5.18 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 950.61 | 5.84 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 950.69 | 7.19 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 951.68 | 6.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 952.63 | 6.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 952.71 | 7.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 953.69 | 7.01 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 953.69 | 7.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 953.71 | 7.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 954.64 | 6.51 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 954.7 | 7.13 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 955.7 | 7.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 956.66 | 7.04 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 956.71 | 7.68 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 956.73 | 8.25 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 957.71 | 7.75 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 958.75 | 8.88 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 967.55 | 4.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 969.57 | 4.86 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 969.61 | 4.99 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 969.61 | 5.32 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 970.61 | 4.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 972.9 | 11.4 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 974.61 | 5.63 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 975.62 | 5 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 976.58 | 5.74 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 980.58 | 5.24 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 982.6 | 5.73 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1002.6 | 5.91 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1004.58 | 5.15 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1006.6 | 5.43 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1007.59 | 4.92 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1008.61 | 5.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1008.61 | 5.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1009.62 | 5.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1009.68 | 7.06 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1010.63 | 6.45 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1023.7 | 7.42 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1030.74 | 6.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1031.7 | 7.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1032.61 | 5.85 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1032.76 | 7.62 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1033.76 | 7.69 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1034.63 | 6.12 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1035.7 | 7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1035.7 | 7.16 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1036.7 | 7.1 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1037.71 | 7.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1049.56 | 4.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1049.68 | 1.54 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1117.7 | 7 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1119.71 | 7.72 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1131.56 | 4.65 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1151.7 | 3.93 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1173.76 | 5.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1175.78 | 5.55 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1176.78 | 5.52 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1178.79 | 5.57 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1189.75 | 4.99 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells | |
AN002019 | 1191.77 | 4.97 | Minutes | ST001211 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Cultured cells |